FUNGI CAN HIDE FROM

Sporanox*

itraconazole 100 mg

One of the notorious problems with fungal infections of the skin or the vagina is that the organism may penetrate the deeper layers of the epithelium, out of reach of topical medication. And besides, when treating fungal skin lesions locally, the infection is often already subclinically present at other sites of the body, waiting for a chance to start the trouble all over again.

Because Sporanox works **orally**, i.e. "from the inside out", it will destroy even the best hidden fungal cells. All the more so, because Sporanox has a strong affinity for epidermal and mucosal tissues as well as for the fungal cell wall itself where it must exert its fungicidal activity.

SHORT AND SIMPLE ORAL THERAPY

Standard dose in Dermatology: 1 capsule (100 mg) once daily for 15 days
(Sporanox will remain active in the stratum corneum for another 3-4 weeks)
Standard dose in Gynaecology: 2 x 2 capsules (400 mg) for 1 day only
(Sporanox will remain active in the vaginal epithelium for another 3 to 4 days)

This product is not yet available in all countries.

*** Trademarks: SPORANOX, SEMPERA, TRISPORAL, SPORAL.**

Properties: Sporanox (itraconazole), a triazole derivative, is orally active against infections with dermatophytes (*Trichophyton* spp., *Microsporum* spp., *Epidermophyton floccosum*), yeasts (*Candida* spp., *Pityrosporum* spp.), *Aspergillus* spp. and various other yeasts and fungi. **Indications:** Sporanox (itraconazole) is indicated for vulvovaginal candidosis, pityriasis versicolor, dermatophytoses, fungal keratitis and oral candidosis. **Dosage and administration:** Vulvovaginal candidosis: 2 capsules (200 mg) morning and evening for 1 day. Pityriasis versicolor: 2 capsules (200 mg) once daily for 7 days. - Tinea corporis, tinea cruris, tinea pedis, tinea manus: 1 capsule (100 mg) daily for 15 days; highly keratinized regions, as in plantar tinea pedis and palmar tinea manus, require 1 capsule (100 mg) daily for 30 days. - Oral candidosis: 1 capsule (100 mg) daily for 15 days. - Fungal keratitis: 2 capsules (200 mg) once daily for 21 days. **Contra-indications:** Sporanox (itraconazole) is contra-indicated during pregnancy. **Warnings and precautions:** Although clinically Sporanox (itraconazole) has not been associated with hepatic dysfunction, it is advisable not to give this drug to patients with a known history of liver disease. **Nursing mothers:** It is recommended not to breast feed whilst taking Sporanox (itraconazole). **Drug interactions:** Sporanox (itraconazole) should not be given concomitantly with rifampicin.

Full prescribing information is available on request.

JANSSEN PHARMACEUTICA
2340 Beerse, Belgium
the drug discovery company

TOBACCO CONTROL

AN INTERNATIONAL JOURNAL

Editor: Ronald M Davis

TOBACCO CONTROL is a new quarterly scientific journal launched in March 1992 by the BMJ Publishing Group to consider all aspects of tobacco prevention and control.

The Journal aims to study:

- The nature and extent of tobacco use worldwide
- The effect of tobacco use on health, the economy, the environment and society.
- The efforts of the health community and health advocates to prevent and control tobacco use
- The activities of the tobacco industry and its allies to promote tobacco use

The [illegible] includ[illegible] editors from [illegible] with ex[illegible] area[illegible] advisory [illegible] tobacco [illegible] and tobacco [illegible] advocates

Research Ar[illegible]

- Evaluation [illegible] cessation pro[illegible]
- Tracking and e[illegible] control policies [illegible]
- Epidemiologic an[illegible] on tobacco use
- Health effects of smoking, smoking cessation, passive smoking and smokeless tobacco use.

Papers from Volume One:

- Trends in physicians' giving advice to stop smoking, United States, 1974-87
  E Gilpin, J Pierce, J Goodman, G Giovino, C Berry, D Burns
- Targeting of cigarette advertising in US magazines, 1959-86
  K E Warner, L M Goldenhar
- Recent developments in tobacco litigation, 1991
  R A Daynard
- Support for restricting smoking at workplaces in develop[illegible] Peace Corps staff
  T R Eng, S L Emont, T H van der Vlugt

Papers for submission should be sent to:

Ronald M Davis, MD
Editor: Tobacco Control
Michigan Department of Public Health
3423 North Logan Street
PO Box 30195
Lansing, Michigan 48909
USA

Subscrip[illegible]
Worldwide [illegible] Personal [illegible]50
(USA only $ 140, [illegible])

*Personal rates are only ava[illegible] orders pla[illegible] with the Publisher and paid [illegible]

Order Form

[illegible]

Essential know-how ×3







"These volumes provide a useful guide to the wide ranging problems physicians have to cope with in their daily practice. They will prove an instructive and easy-to-read reference tool for all those involved with patient management, hospital organisation and research." *International Surgery*

The reviewers say . . .

HOW TO DO IT: 1

". . . an excellent little book." *American Journal of Dermatology*

"Every contribution contains something of interest." *New Zealand Medical Journal*

". . . equally suitable for medical student and consultant." *Journal of the Royal Naval Medical Service*

HOW TO DO IT: 2

". . . contains a wealth of useful information and advice which the experienced contributors have gleaned from long professional experience." *British Dental Journal*

". . . a useful and informative book . . ." *Medical Journal of Australia*

". . . this book is excellent value and should be considered a vital resource for all doctors . . ." *Holistic Medicine*

HOW TO DO IT: 3

"I cannot think of any book that provides better value than this interesting volume for the modern doctor." *Update*

"All articles are clearly presented, informative and written in a relaxed often humorous style." *Scottish Medical Journal*

"The style of writing is eminently readable and the information is delivered in a reader-friendly style." *SAMJ*

Price (each book): UK £7.95; Abroad £9.50 (BMA members £7.45 or £9.00)

ORDER FORM British Medical Journal, PO Box 295, London WC1H 9TE.

Please send me the following books:

QTY	TITLE	AUTHOR/EDITOR	AMOUNT
		TOTAL £	

Prices include postage, by air abroad

NAME _____
(print clearly)

ADDRESS _____

_____

_____ POSTCODE _____

☐ Please send me a book catalogue

Membership No _____

Cheque enclosed (made payable to British Medical Journal) £ _____

Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Card No _____ Exp _____

Signature _____

BMJ books are also available from major booksellers or the BMJ bookshop in BMA House. Book tokens accepted (UK only).



Gra ith

Founded in 1923, one year after the first anaesthetic journal was published by the International Anaesthesia Research Society, the *British Journal of Anaesthesia* remained the oldest and the largest independent journal of anaesthesia, until 1990 when it became the official journal of the newly formed College of Anaesthetists.

The highly cited *British Journal of Anaesthesia*, publishes original work in all branches of anaesthesia, including the application of basic sciences, together with review articles and new equipment reports. All subscribers also receive the ***Handbook of Anaesthesia***, an annual compendium of information of anaesthetic interest at the national level, in a single source reference.

All papers are subject to peer review, and this together with emphasis on clarity and rapid publication has enabled *British Journal of Anaesthesia* to become the most widely read anaesthetic journal in Europe and a leading international journal in the specialty.

RECENT ARTICLES:

Recognition and management of difficult airway problems
M Cobley and R S Vaughan

Diabetes and anaesthesia: the past decade
L R M Milaskiewicz and G M Hall

Double blind comparison of the morphine sparing effect of continuous and intermittent IM administration of ketorolac.
J W Burns, H A Aitken, R E S Bullingham, C S McArdle and G N C Kenny

Clearance of atracurium and laudanosine in the urine and by continuous venovenous haemofiltration
E S Shearer, E P O'Sullivan and J M Hunter

1992 Subscription Rate: £117, (USA only: $180)
Trainee rates are available, please complete the order form for details

---

ORDER FORM

BRITISH JOURNAL OF ANAESTHESIA
1992 SUBSCRIPTION RATE: £117, (USA ONLY: $180)

ISSN: 0007-0912 **PUBLICATION: Monthly**

Please tick

☐ Please enter my subscription, start date _____
☐ Please send me a sample copy
☐ Please send me information regarding the Special Trainee rates
☐ Please send me *Instructions to Authors*
☐ I enclose a cheque for _____
(Payable to Professional and Scientific Publications)
☐ I wish to pay by credit card.
American Express/Visa(Barclaycard)/Mastercard
(Delete as appropriate)

Card Number ☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐ ☐☐☐☐ **Expiry date** _____
MasterCard users should add the numbers appearing above their name

Signature _____
(Your signature is essential, especially when paying by credit card)

Name *(Capitals)* _____

Address _____

_____

_____ **Date** _____

BMJ

Send orders to: **BMJ Publishing Group, BMA House, Tavistock Square, London. WC1H 9JR.**
or BMJ Publishing Group, Box No 560B, Kennebunkport, Maine 04046, USA.

Are the ills of middle and later life rooted in our early development?



Based on an original embroidery by Dean Design

During the past few years a series of articles, mostly from the Medical Research Council's Environmental Epidemiology Unit at the University of Southampton, has been published in leading medical journals. They set out the evidence that certain adult diseases, including coronary heart disease, stroke and diabetes originate in impaired development during fetal life and infancy. Because of the obvious implications for prevention of some of the commonest diseases in Western society, they have attracted international attention. In this book, Professor David Barker, Director of the Unit, has selected 31 articles that he considers seminal and a comprehensive guide to the development of this important topic. Professor Roger Robinson's introduction summarises and interprets the evidence for non-epidemiologists.

The first chapters describe the origins of the hypothesis in geographical studies in England and Wales. These are followed by a series of studies of men and women in middle and late life whose early growth was recorded at the time. In those who have died, cause of death can be related to early growth. Examination of the living has allowed blood pressure, blood lipid and insulin concentrations, and other measurements to be related to different patterns of early growth. Together, the findings show that early development affects the risk of coronary heart disease, stroke, obstructive lung disease and diabetes at least as strongly as obesity, smoking and other aspects of adult life style.

Fetal and Infant Origins of Adult Disease brings together in one volume a body of work that cannot be ignored

Hardback • Illustrations • Tables • 368 pages • ISBN 0-7279-0743-3

UK £24.95; Abroad £30.00 (BMA members £22.95 or £28.00) including postage, by air abroad

✂

ORDER FORM **British Medical Journal, PO Box 295, London WC1H 9TE.**

Please send me _____ copy/ies of FETAL AND INFANT ORIGINS OF ADULT DISEASE

NAME _____
(print clearly)

ADDRESS _____

_____

_____ POSTCODE _____

☐ Please send me a book catalogue

Membership No _____

Cheque enclosed (made payable to British Medical Journal) £ _____

Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Card No _____ Exp _____

Signature _____

BMJ books are also available from major booksellers or the BMJ bookshop in BMA House. Book tokens accepted (UK only).

gastric distress & oesophagitis

hyperacidity or dysmotility?

Most complaints of gastric distress, as well as oesophagitis, are conventionally attributed to hyperacidity in the stomach. However, the contemporary view in gastroenterology holds that most upper G.I. problems, including heartburn, postprandial fullness, early satiety, abdominal distension and epigastric discomfort, are commonly motility related.[1-3] And this stands to reason. After all, proper peristalsis is a physiological necessity for our digestive process.

Prepulsid, the novel G.I. prokinetic, uniquely restores healthy peristalsis to efficiently clear the oesophagus and empty the stomach.[4-6]



TRADEMARK

Prepulsid

CISAPRIDE

restores upper G.I. motility like no other agent.

JANSSEN
PHARMACEUTICA
B-2340 Beerse, Belgium

expertise in digestive motility

Eur J Phi 1991 References: 1. Knuff, J.E. et al: Dig Dis Sci. 29: 194 (1984) 2. Kahrilas, J.P. et al: Gastroenterology 91: 897 (1986) 3. Malagelada, J.R. et al: Gastroenterol 88: 1223 (1985) 4. Ceccarelli, P. et al: Gut 29: 631 (1988) 5. Collins, B.J. et al: Hepato-Gastroenterol 34: 113 (1987) 6. Jian, R. et al: Dig Dis Sci. 34: 657 (1989)

Prescribing Information - Prepulsid (cisapride) is a gastro-intestinal prokinetic agent. Prepulsid enhances and co-ordinates gastro-intestinal propulsive motility, thereby preventing stasis and reflux. **Therapeutic indications**: 1. Gastroparesis. 2. Symptoms of X-ray or endoscopy negative upper digestive discomfort. 3. Gastro-oesophageal reflux disorders, including oesophagitis. 4. Intestinal pseudo-obstruction. **Contra-indications**. No absolute contra-indications are known. **Precautions**: *Pregnancy*: Although, in animals, there is no effect on primary fertility, no primary embryotoxic and no teratogenic effect, the anticipated therapeutic benefits should be weighed against the potential hazards before Prepulsid is given during pregnancy, especially during the first trimester. *Nursing mothers*: Although the excretion in breast milk is minimal, nursing mothers are advised not to breast feed while taking Prepulsid. *Driving and machine-operating ability*: Prepulsid does not affect psychomotor function and does not induce sedation or drowsiness. Prepulsid may, however, accelerate the absorption of central nervous system depressants, such as barbiturates and alcohol. Caution should therefore be exercised when Prepulsid is administered with these drugs. **Interactions**: - The acceleration by Prepulsid of gastric emptying may affect the rate of absorption of drugs: absorption of drugs from the small bowel may be accelerated (e.g. benzodiazepines, anticoagulants, paracetamol, H_2-blockers). - In patients receiving anticoagulants, the coagulation times may somewhat increase. It is advisable to check the coagulation time one week after the start of Prepulsid treatment to adapt the anticoagulant dose if necessary. - The effects of Prepulsid on gastro-intestinal motility are, for the most part, antagonized by anticholinergic drugs. - In hepatic and renal insufficiency, it is recommended to halve the initial daily dose. Subsequently, this dose can be adapted, depending on the therapeutic effect desirable or possible side effects. - In the elderly, steady-state plasma levels are generally higher, due to a moderate prolongation of the elimination half-life. Therapeutic doses, however, are similar to those used in younger patients. - In the case of drugs that require individual titration, it may be useful to monitor plasma levels of such drugs when Prepulsid is associated. **Adverse reactions**: In line with the pharmacological activity of Prepulsid, transient abdominal cramping, borborygmi and diarrhoea may occur. Mild and transient headache or lightheadedness have been reported occasionally. When diarrhoea occurs in babies or infants, the dose should be reduced. There have been isolated reports of convulsive seizures without clearcut relationship to Prepulsid. **Dosage**: - Adults: according to the severity of the condition, 5 or 10 mg of Prepulsid, 2 to 4 times daily, to be taken as tablets or as oral suspension (the full plastic 5-ml spoon contains 5 mg). As a rule the following doses have proven adequate: • less severe conditions (gastroparesis, oesophagitis, refractory constipation): 10 mg t.i.d. to 10 mg q.i.d. (before the 3 main meals and before retiring); • severe conditions (gastroparesis, oesophagitis, refractory constipation): 10 mg t.i.d. (dose can be doubled); • infants and children: on the average 0.2 mg/kg per intake, 3 to 4 times daily. For the suspension, intakes are indicated on the dosing pipet as a function of body weight.

Note: Prepulsid (cisapride) is not yet available in all countries and not all indications have been approved everywhere.

Full prescribing information available on request.